209 related articles for article (PubMed ID: 11163814)
1. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.
Fluker M; Grifo J; Leader A; Levy M; Meldrum D; Muasher SJ; Rinehart J; Rosenwaks Z; Scott RT; Schoolcraft W; Shapiro DB;
Fertil Steril; 2001 Jan; 75(1):38-45. PubMed ID: 11163814
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of using ganirelix acetate versus a 4-day follicular phase leuprolide acetate protocol in unselected women undergoing in vitro fertilization.
Posada MN; Vlahos NP; Jurema MW; Bracero NJ; Wallach EE; Garcia JE
Fertil Steril; 2003 Jul; 80(1):103-10. PubMed ID: 12849810
[TBL] [Abstract][Full Text] [Related]
3. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
Borm G; Mannaerts B
Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
[TBL] [Abstract][Full Text] [Related]
6. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.
European and Middle East Orgalutran Study Group
Hum Reprod; 2001 Apr; 16(4):644-51. PubMed ID: 11278211
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates.
Qiao J; Lu G; Zhang HW; Chen H; Ma C; Olofsson JI; Witjes H; Heijnen E; Mannaerts B
Gynecol Endocrinol; 2012 Oct; 28(10):800-4. PubMed ID: 22429192
[TBL] [Abstract][Full Text] [Related]
8. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.
Kol S; Lightman A; Hillensjo T; Devroey P; Fauser B; Tarlatzis B; Mannaerts B; Itskovitz-Eldor J
Hum Reprod; 1999 Sep; 14(9):2242-4. PubMed ID: 10469687
[TBL] [Abstract][Full Text] [Related]
9. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction.
Sauer MV; Thornton MH; Schoolcraft W; Frishman GN
Reprod Biomed Online; 2004 Nov; 9(5):487-93. PubMed ID: 15588464
[TBL] [Abstract][Full Text] [Related]
11. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial.
Lambalk CB; Leader A; Olivennes F; Fluker MR; Andersen AN; Ingerslev J; Khalaf Y; Avril C; Belaisch-Allart J; Roulier R; Mannaerts B
Hum Reprod; 2006 Mar; 21(3):632-9. PubMed ID: 16361296
[TBL] [Abstract][Full Text] [Related]
12. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
[TBL] [Abstract][Full Text] [Related]
13. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
[TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients.
MartÃnez F; Clua E; Parera N; RodrÃguez I; Boada M; Coroleu B
Gynecol Endocrinol; 2008 Apr; 24(4):188-93. PubMed ID: 18382904
[TBL] [Abstract][Full Text] [Related]
15. A comparison of pregnancy rates following fresh and frozen embryo transfer according to the use of leuprolide acetate vs ganirelix vs cetrorelix.
Check JH; Wilson C; Choe JK; Amui J; Katsoff B
Clin Exp Obstet Gynecol; 2010; 37(2):105-7. PubMed ID: 21077496
[TBL] [Abstract][Full Text] [Related]
16. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome.
Gustofson RL; Segars JH; Larsen FW
Hum Reprod; 2006 Nov; 21(11):2830-7. PubMed ID: 16966348
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program.
Chang YS; Kim SH; Shin CJ; Kim JG; Moon SY; Lee JY
Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):337-45. PubMed ID: 2129188
[TBL] [Abstract][Full Text] [Related]
18. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
[TBL] [Abstract][Full Text] [Related]
19. Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome.
Elkind-Hirsch KE; Webster BW; Brown CP; Vernon MW
Fertil Steril; 2003 Mar; 79(3):603-7. PubMed ID: 12620447
[TBL] [Abstract][Full Text] [Related]
20. A prospective comparison of in vitro fertilization (IVF) outcome following controlled ovarian hyperstimulation (COH) regimens using follitropin alpha exclusively or with the addition of low dose human chorionic gonadotropin (hCG) and ganirelix.
Check JH; Davies E; Brasile D; Choe JK; Amui J
Clin Exp Obstet Gynecol; 2009; 36(4):217-8. PubMed ID: 20101851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
